Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA–PEG block copolymersY.K. Luu, Michael Hadjiargyrou, Kihyun Kım et al.|Journal of Controlled Release|2003Cited by 793
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVânia Hungria, María-Victoria Mateos, Tomoaki Fujisaki et al.|New England Journal of Medicine|2024Cited by 162
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patientsS.T. Kim, Kimberly C. Banks, Eirini Pectasides et al.|Annals of Oncology|2018Cited by 105
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosisJi-Yun Lee, Kihyun Kım, Sung Hee Lim et al.|Amyloid|2014Cited by 23
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).María‐Victoria Mateos, Vânia Hungria, Paweł Robak et al.|Journal of Clinical Oncology|2024Cited by 21